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IRSp53 (also known as BAIAP2) is a multi-domain scaffolding and adaptor protein that has been
implicated in the regulation of membrane and actin dynamics at subcellular structures, including ﬁlo-
podia and lamellipodia. Accumulating evidence indicates that IRSp53 is an abundant component of the
postsynaptic density at excitatory synapses and an important regulator of actin-rich dendritic spines. In
addition, IRSp53 has been implicated in diverse psychiatric disorders, including autism spectrum dis-
orders, schizophrenia, and attention deﬁcit/hyperactivity disorder. Mice lacking IRSp53 display enhanced
NMDA (N-methyl-D-aspartate) receptor function accompanied by social and cognitive deﬁcits, which are
reversed by pharmacological suppression of NMDA receptor function. These results suggest the hy-
pothesis that defective actin/membrane modulation in IRSp53-deﬁcient dendritic spines may lead to
social and cognitive deﬁcits through NMDA receptor dysfunction.
This article is part of the Special Issue entitled ‘Synaptopathy e from Biology to Therapy’.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
IRSp53 (for insulin receptor substrate p53), also known as
BAIAP2 (brain-speciﬁc angiogenesis inhibitor 1-associated protein
2), is a multi-domain adaptor protein originally identiﬁed as a
protein that is tyrosine phosphorylated by the insulin receptor and
IGF-1 (insulin-like growth factor 1) receptor (Yeh et al., 1996).
Subsequent studies have ﬁrmly established IRSp53 as an important
regulator of membrane and actin dynamics at actin-rich subcellular
structures, including ﬁlopodia and lamellipodia (Ahmed et al.,
2010; Scita et al., 2008; Suetsugu et al., 2010).
Although the functions of IRSp53 have been mainly studied in
non-neural cells, steadily accumulating evidence supports neuronal
functions of IRSp53, in particular, in the regulation of membrane/
actin dynamics at excitatory synapses and dendritic spines. The
ﬁrst such evidence was a report that identiﬁed IRSp53 as an
important component of the postsynaptic density (PSD) (Abbott
et al., 1999)dmulti-protein complexes in the postsynaptic side of
excitatory synapses that couple receptor activation withn Dysfunctions, Institute for
Ltd. This is an open access article udownstream signaling (Emes and Grant, 2012; Kennedy, 1993;
Sheng and Hoogenraad, 2007; Sheng and Kim, 2011).
More recently, IRSp53/BAIAP2 has been implicated in several
psychiatric disorders, including autism spectrum disorders (ASDs)
(Celestino-Soper et al., 2011; Levy et al., 2011; Toma et al., 2011),
schizophrenia (Fromer et al., 2014; Purcell et al., 2014), and atten-
tion deﬁcit/hyperactivity disorder (ADHD) (Liu et al., 2013; Ribases
et al., 2009). In parallel, neurobiological studies on mice lacking
IRSp53 (IRSp53/ mice) have revealed that IRSp53 deletion leads
to synaptic and behavioral abnormalities that are reminiscent of
symptoms of IRSp53-related psychiatric disorders, suggesting the
possibility of IRSp53-related synaptopathies.
In this review, wewill summarize the reported roles of IRSp53 in
the regulation of membrane/actin dynamics, dendritic spine
development, NMDA receptor (NMDAR) function, and social and
cognitive behaviors. In addition, wewill discuss how the deletion of
the IRSp53 gene leads to enhanced NMDA (N-methyl-D-aspartate)
receptor (NMDAR) function, which is associated with social and
cognitive deﬁcits in IRSp53/ mice.2. Domain structure of IRSp53
The IRSp53 gene is located at human chromosome 17q25 and
mouse chromosome 11E2. These genes are predicted to consist ofnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The IRSp53 protein contains multiple domains for proteine-
protein interactions, including an IMD (IRSp53-MIM homology
domain; also known as an I-BAR) domain, a CRIB-PR (Cdc42/Rac
interactive binding-proline rich) domain, an SH3 (Src homology 3)
domain, a WW domain, a WH2 (WASP homology 2) domain, and a
C-terminal PDZ-B (PSD-95/Dlg/ZO-1 domain-binding) motif
(Fig. 1A). The IMD/I-BAR domain is known to bind to and deform
the plasma membrane, creating a negative membrane curvature
(Suetsugu et al., 2010).
IRSp53 shares a similar domain structure, with the exception of
the CRIB-PR domain (Yamagishi et al., 2004), with two otherFig. 1. Domain structure, splice variants, and activation mechanisms of IRSp53. (A) Doma
variations are mainly observed in C-terminal regions, except for the B form in mice lacking a
interactive binding-proline rich domain; SH3, Src homology 3 domain; WW, WW domain;
Autoinhibition and activation mechanisms in IRSp53. Head-to-head dimers of IRSp53 are aut
CRIB-PR and SH3 domains. Binding of activated (GTP-bound) Cdc42 to the CRIB-PR domain o
WASP and WAVE2.members of the IRSp53 subfamily of IMD-containing proteins:
IRTKS (insulin receptor tyrosine kinase substrate; also known as
BAIAP2L1), which is minimally expressed in the brain (Millard et al.,
2007), and FLJ22582 (BAIAP2L2), which has been minimally stud-
ied (Yamagishi et al., 2004). Drosophila and Caenorhabditis elegans
also have proteins with a similar domain structure (Yamagishi et al.,
2004).
Alternative splicing generates a total of ﬁve splice variants of
IRSp53, four in humans and three in mice, four of whichdS, L, M,
and T formsdmainly differ in the C-terminal region, sharing the
ﬁrst 511 aa residues, whereas the ﬁfth, termed the B form here
(IRSp53-B), lacks ~40 aa in the CRIB-PR domain (Alvarez andin structure and splice variants identiﬁed in humans and mice. Note that the splice
part of the CRIB-PR domain. IMD, IRSp53-MIM homology domain; CRIB-PR, Cdc42/Rac
PDZ-B, PSD-95/Dlg/ZO-1 domain-binding motif; WH2, WASP homology 2 domain. (B)
oinhibited in a closed conformation through an intramolecular interaction involving the
pens up the protein, allowing the SH3 domain to bind downstream effectors such as N-
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1999; Okamura-Oho et al., 1999). These variants could be func-
tionally distinct because the S and L forms are phosphorylated by
insulin stimulation, whereas the T form is phosphorylated by IGF-1
stimulation (Okamura-Oho et al., 2001).
There are two major IRSp53 protein species in rodent brains
with apparent molecular masses of ~58 and 53 kDa. The molecular
nature of these proteins is unclear, although they likely represent
the S from with or without the 40-aa splice insert in the CRIB-PR
domain. In support of this possibility, immunoblotting and
reverse transcription-polymerase chain reaction (RT-PCR) data
indicate that the S variant is the main isoform expressed in rat
cultured hippocampal neurons (Hori et al., 2005). Both IRSp53
species coimmunoprecipitate with the excitatory postsynaptic PDZ
protein PSD-95 in rat brains (Choi et al., 2005; Soltau et al., 2004),
suggesting that they both have the PDZ-B motif, which is present in
the S form. In vitro protein translation of mouse S forms with or
without the 40-aa insert yields protein species of ~58 and 53 kDa
(Alvarez et al., 2002). Post-translational modiﬁcation is unlikely to
account for the two bands, because the 5 kDa difference between
them is unlikely to be caused by protein phosphorylation, and
deglycosylation enzymes have no effect on the protein band sizes
(Abbott et al., 1999). Functionally, if the 58 and 53 kDa proteins
differ in the CRIB-PR domain, they are likely to have distinct
autoinhibitory mechanisms (see below for details).
3. Expression patterns of IRSp53 mRNAs and proteins
Northern blot analyses indicate that IRSp53 is expressed most
strongly in the brain, but also in other tissues, including the spleen,
lung, liver, and testis (Abbott et al., 1999; Bockmann et al., 2002). In
the brain, IRSp53 mRNAs are detected in regions including the
cortex, hippocampus, striatum, and cerebellum (Bockmann et al.,
2002).
At the protein level, IRSp53 expression, measured by X-gal
staining of IRSp53þ/ mouse brain slices, is observed in regions
including the cortex, hippocampus, striatum, and cerebellum (Kim
et al., 2009a; Sawallisch et al., 2009), a distribution pattern similar
to that of the corresponding mRNA. In addition, Immunohisto-
chemical analyses with speciﬁc IRSp53 antibodies indicate a similar
distribution pattern of endogenous IRSp53 proteins in rat brains
(Bockmann et al., 2002; Burette et al., 2014).
4. Protein interactions of IRSp53
A role for IRSp53 in the regulation of membrane and actin dy-
namics is supported by the fact that IRSp53 interacts with mem-
branes, actin ﬁlaments, small GTPases, actin regulatory proteins,
and PDZ domain-containing scaffolding proteins. Many of these
proteins regulate neuronal/synaptic functions, and some have been
implicated in brain disorders (Table 1).
The N-terminal IMD domain binds and deforms PI(4,5)P2- and
PI(3,4,5)P3-rich membranes through its I-BAR activity (Mattila
et al., 2007; Suetsugu et al., 2006). In addition, the IMD domain
of IRSp53 binds and bundles actin ﬁlaments (Yamagishi et al.,
2004), although its role in membrane deformation is unclear
(Safari and Suetsugu, 2012). Two IMD domains form an anti-
parallel dimer (Millard et al., 2005), leading to the dimerization
of full-length IRSp53 proteins in a head-to-head manner (Fig. 1B).
The CRIB-PR domain binds the GTP-bound (activated) form of the
small GTPase Cdc42 (Govind et al., 2001; Krugmann et al., 2001).
Because Cdc42 itself is tethered to the plasmamembrane, both IMD
and Cdc42 contribute to the membrane targeting of IRSp53, in line
with the concept that phosphoinositides and small GTPases act in
synergy to recruit cytoplasmic proteins to speciﬁc compartments ofthe plasma membrane (Di Paolo and De Camilli, 2006).
In the full-length IRSp53 protein, interaction of the SH3 domain
with binding partners is thought to be inhibited through an intra-
molecular interaction involving the CRIB-PR and SH3 domains
(Alvarez et al., 2002; Disanza et al., 2006; Kast et al., 2014). This
autoinhibition of IRSp53 is relieved by Cdc42 binding to the CRIB-
PR domain (Alvarez et al., 2002; Govind et al., 2001; Kast et al.,
2014; Krugmann et al., 2001), allowing the SH3 domain to bind
its effectors. Many of these effectors are actin modulatory proteins
such as WAVE-2, N-WASP, Eps8, Ena/VASP, and mDia1, which in
many cases converge onto the Arp2/3 complex (Table 1), known to
promote nucleation of branched actin ﬁlament networks (Scita
et al., 2008). The autoinhibition of IRSp53 also suppresses the
interaction of the IMD domain with membranes, as supported by
the limited localization of the autoinhibited protein in the plasma
membrane (Kast et al., 2014).
In addition to regulating actin dynamics, the SH3 effectors of
IRSp53 enhance additional opening/activation of IRSp53. For
instance, dual binding of Cdc42 and SH3 effectors such as Eps8
(Funato et al., 2004), to IRSp53 synergistically induces full opening/
activation of IRSp53 (Disanza et al., 2006; Kast et al., 2014). WAVE-2
binding to the SH3 domain enhances Rac1 binding to the IMD
domain (Miki and Takenawa, 2002; Miki et al., 2000). In addition,
some SH3 effectors such as Tiam1 (a guanine nucleotide exchange
factor or GEF for Rac) and Eps8 (coupled to Sos-1 and Abi-1, both
with Rac-GEF activities) activate Rac1 (Connolly et al., 2005; Funato
et al., 2004), suggesting that IRSp53 can act both upstream and
downstream of Rac. Thesemechanisms are thought to contribute to
IRSp53-dependent formation of actin-rich protrusive structures
such as ﬁlopodia (Govind et al., 2001; Krugmann et al., 2001;
Yamagishi et al., 2004) and lamellipodia (Miki et al., 2000) at the
interface of membranes and actin ﬁlaments.
The WH2 domain is generally known to bind monomeric actin,
but the WH2 domain in IRSp53 is dissimilar to canonical WH2
domains, and thus its function is unclear (Scita et al., 2008). Lastly,
the C-terminal PDZ-binding (PDZ-B) motif interacts with diverse
PDZ domain-containing scaffolding proteins, including PSD-95,
PSD-93/Chapsyn-110, and MALS/LIN-7 (Choi et al., 2005; Hori
et al., 2003; Soltau et al., 2004).
5. Synaptic localization of IRSp53
Since the identiﬁcation of IRSp53 as a core component of the
PSD and excitatory synapses (Abbott et al., 1999), additional
experimental evidence has supported the excitatory synaptic
localization of IRSp53. For instance, in situ hybridization and
immunoblot analyses of biochemical rat brain fractions indicate
that IRSp53 expression is signiﬁcantly increased during the ﬁrst 3
weeks of postnatal brain development (Bockmann et al., 2002; Choi
et al., 2005), during which active synaptogenesis occurs.
Ultrastructural electron microscopy (EM) indicates that IRSp53
proteins are present in the PSD as well as at other sub-regions of
dendritic spines such as tangential walls and spine cytosolic regions
(Choi et al., 2005). A more recent EM study reported that IRSp53
displays distinct distribution patterns within the PSD in different
brain regions. In spiny excitatory neurons of the neocortex and
hippocampus, IRSp53 is concentrated in the center of the PSD
rather than in the periphery, whereas it is uniformly distributed
along the lateral axis of the PSD in spiny inhibitory neurons of the
neostriatum and cerebellar cortex (Burette et al., 2014). The reasons
for these differences are unclear.
Synaptic localization of IRSp53 appears to be regulated by
neuronal activity. NMDA receptor stimulation in cultured hippo-
campal neurons promotes synaptic localization of IRSp53 in a
manner requiring protein kinase C activation, the IMD and PDZ-B
Table 1
Binding partners of IRSp53 and their neuronal/synaptic functions and associations with brain disorders.
Domain Binding partner Function of interaction Partner's neuronal/synaptic
function
Partner's association with brain
disorders
IMD F-actin (Yamagishi et al., 2004) Actin bundling (Yamagishi
et al., 2004)
Main cytoskeleton in dendritic
spines
IRSp53 (Millard et al., 2005) Forms IRSp53 dimers (Millard
et al., 2005)
Actin and membrane dynamics
in spines (Scita et al., 2008)
ASD, schizophrenia, and ADHD
(See Table 3 for details)
Kank1 (Roy et al., 2009) Inhibits Rac1-IRSp53
interaction (Roy et al., 2009)
Suppresses actin ﬁlament
formation (Kakinuma et al.,
2008)
Cerebral palsy (Lerer et al.,
2005)
ASD, motor/cognitive
dysfunctions (Vanzo et al.,
2013)
Rac1 (Miki et al., 2000) Links Rac1 and Wave (Miki
et al., 1998; Miki et al., 2000)
Membrane deformation
(Suetsugu et al., 2006)
Neuronal development (Govek
et al., 2005; Tolias et al., 2011)
CRIB-PR Cdc42 (Govind et al., 2001;
Krugmann et al., 2001)
Relieves autoinhibition
(Krugmann et al., 2001)
Neuronal development (Govek
et al., 2005; Tolias et al., 2011)
Between CRIB-PR
and SH3
14-3-3z (Robens et al., 2010) Inhibits IRSp53 binding to SH3
effectors and Cdc42 (Robens
et al., 2010)
Neural signaling, development,
and protection (Foote and Zhou,
2012)
ASD (Toma et al., 2013)
SH3 BAI1 (Oda et al., 1999) Localizes IRSp53 to membranes
(Oda et al., 1999)
Synaptogenesis and spine
formation (Stephenson et al.,
2014)
BRAG1/IQ-ArfGEF (Sanda et al.,
2009)
Regulate ARF signaling in
dendritic spines (Sanda et al.,
2009)
Synaptic plasticity (Myers et al.,
2012)
Intellectual disability
(Shoubridge et al., 2010)
Cypin (Barilari and Dente, 2010) Form the CIPP-Cypin-IRSp53
complex (Barilari and Dente,
2010)
Microtubules and dendrite
patterning (Tseng and Firestein,
2011)
DRPLA/Atrophin-1 (Okamura-
Oho et al., 1999)
May regulate insulin/IGF-1
signaling pathways (Okamura-
Oho et al., 1999)
Transcriptional co-repressor
(Shen and Peterson, 2009)
DRPLA (Tsuji, 2012)
Dynamin1 (Chou et al., 2014) Promotes ﬁlopodia formation
(Chou et al., 2014)
Membrane ﬁssion during
endocytosis (Ferguson and De
Camilli, 2012)
Epilepsy (Ferguson and De
Camilli, 2012)
Eps8 (Funato et al., 2004) Activates IMD-bound Rac
(Funato et al., 2004)
Dendritic spines (Menna et al.,
2013; Stamatakou et al., 2013)
ASD (Menna et al., 2013)
Espin (Sekerkova et al., 2003) Regulates actin binding and
bundling (Sekerkova et al.,
2003)
Stereociliary actin bundle
(Sekerkova et al., 2011).
Deafness, vestibular
dysfunction (Naz et al., 2004)
mDia1 (Fujiwara et al., 2000) Promotes ﬁlopodia formation
(Goh et al., 2012)
Migration of interneuron
precursors (Shinohara et al.,
2012)
Mena (Krugmann et al., 2001) Induces ﬁlopodia formation
(Krugmann et al., 2001)
Neuronal polarity (Drees and
Gertler, 2008; Neukirchen and
Bradke, 2011)
Links gephyrin to actin (Bausen
et al., 2006; Giesemann et al.,
2003)
N-WASP (Lim et al., 2008) Promotes ﬁlopodia formation
(Lim et al., 2008)
Neurite and spine development
(Irie and Yamaguchi, 2004;
Suetsugu et al., 2002; Wegner
et al., 2008)
SH2B1 (Hong et al., 2014) Promotes ﬁlopodia formation
(Hong et al., 2014)
Dendrite formation and
branching (Chen et al., 2015)
Developmental delay
(Bachmann-Gagescu et al.,
2010)
Shank1 (Soltau et al., 2002) Links Shank1 to Cdc42 and PSD-
95 (Choi et al., 2005; Soltau
et al., 2002)
Spine morphology and synaptic
function (Sala et al., 2001)
ASD (Leblond et al., 2014; Sato
et al., 2012)
Schizophrenia (Lennertz et al.,
2012)
Shank3 (Bockmann et al., 2002) Induces ﬁlopodia outgrowth in
neuronal cell lines (Bockmann
et al., 2002)
Dendritic spines (Roussignol
et al., 2005)
ASD, Phelan-McDermid
syndrome, schizophrenia,
bipolar, hyperkinetic
(Guilmatre et al., 2014; Han
et al., 2013; Leblond et al., 2014)
Spin90 (Teodorof et al., 2009) Regulates Rac/Rho and actin
ﬁlaments (Teodorof et al., 2009)
Dendritic spines (Cho et al.,
2013; Kim et al., 2009b;
Wagner et al., 2013)
Synaptopodin (Yanagida-
Asanuma et al., 2007)
Inhibit Cdc42 andMena binding
to IRSp53 (Yanagida-Asanuma
et al., 2007)
Spine apparatus and spine
plasticity (Korkotian et al.,
2014)
Tiam1 (Connolly et al., 2005) Contributes to Rac signaling
speciﬁcity (Connolly et al.,
2005)
Spine development (Tolias
et al., 2005; Tolias et al., 2007)
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Table 1 (continued )
Domain Binding partner Function of interaction Partner's neuronal/synaptic
function
Partner's association with brain
disorders
VASP (Disanza et al., 2013) Promotes ﬁlopodia formation
(Disanza et al., 2013)
Neuronal polarity (Drees and
Gertler, 2008; Neukirchen and
Bradke, 2011)
Wave-1 (Miki et al., 2000) Links Rac and Wave (Miki et al.,
1998; Miki et al., 2000)
Spines, synaptic plasticity, and
memory (Hazai et al., 2013; Kim
et al., 2006; Soderling et al.,
2007)
Wave-2 (Miki et al., 2000) Links Rac and Wave (Miki et al.,
1998; Miki et al., 2000)
Likely dendritic spines (Choi
et al., 2005; Ito et al., 2010; Lee
et al., 2006; Soderling and Scott,
2006)
PDZ-B CIPP (Alpi et al., 2009; Barilari
and Dente, 2010)
Form the CIPP-Cypin-IRSp53
complex (Barilari and Dente,
2010)
Synaptic membrane protein
clustering (Kurschner et al.,
1998)
ASD and Schizophrenia (Kenny
et al., 2014)
MALS/LIN-7 (Hori et al., 2003) May translocate IRSp53 to cell
ecell contacts (Hori et al., 2003)
Synapse development and
function (Mizuno et al., 2015)
ASD (Mizuno et al., 2015)
PSD-93 (Choi et al., 2005) Synaptic localization of IRSp53
(Choi et al., 2005)
Postsynaptic protein scaffolding
(Sheng and Kim, 2011)
ASD (Egger et al., 2014)
PSD-95 (Choi et al., 2005; Soltau
et al., 2004)
Synaptic localization of IRSp53
(Choi et al., 2005)
Postsynaptic protein scaffolding
(Sheng and Kim, 2011)
ASD and William's syndrome
(Feyder et al., 2010)
Schizophrenia (Balan et al.,
2013; Purcell et al., 2014)
J. Kang et al. / Neuropharmacology 100 (2016) 27e39 31domains of IRSp53, and protein kinase C-dependent phosphoryla-
tion of the IMD domain (Hori et al., 2005).
6. IRSp53 in dendritic spine development
Dendritic spines, protrusions in neurons with distinct mem-
brane curvatures in sub-regions (i.e. head, wall, and neck), are well
known for their actin-rich cytoskeleton (Cingolani and Goda, 2008;
Harris and Weinberg, 2012; Penzes and Rafalovich, 2012; Sala and
Segal, 2014; Tada and Sheng, 2006). Therefore, IRSp53, a regulator
of membrane and actin dynamics, could be expected to play a role
in the regulation of dendritic spine development and plasticity.
Dendritic spines contain a branched actin ﬁlament network in
the head, and a network of branched and linear actin ﬁlaments in
the spine neck and in dendritic ﬁlopodia (a possible precursor of
dendritic spines), which are reported to contain tightly bundled
actin ﬁlaments (Korobova and Svitkina, 2010). These authors sug-
gest that an actin patch on the dendritic trunk elongates into a
ﬁlopodium, and the tip expands into a mature spine head through
the activity of the Arp2/3 complex, known to regulate dendritic
spine structure and plasticity (Kim et al., 2013, 2015).
Providing a more dynamic view of spine actin regulation, a
recent study using single protein tracking and super-resolution
imaging has revealed an interesting nanoscale sub-spine segrega-
tion, where regulators of F-actin nucleation/branching such as
IRSp53 and the WAVE complex are conﬁned at the vicinity the PSD,
whereas F-actin elongators such as VASP and formin-like protein-2
move outwards from the PSD with protrusion tips (Chazeau et al.,
2014). This study also ﬁnds that Rac1 reaches the PSD through
membrane free-diffusion and is immobilized at the PSD depending
on its levels of activation, whereas the Arp2/3 complex reaches to
the PSD through cytosolic free-diffusion. Moreover, conditions
promoting spine enlargement such as constitutively active Rac1, or
overexpressed Shank3, delocalize theWAVE complex from the PSD,
and translocate the complex to the other parts of the spine to
promote F-actin elongation throughout the spine.
Overexpression of IRSp53 in dissociated cultured hippocampal
neurons increases spine density and size (Choi et al., 2005).
Knockdown of IRSp53 decreases spine density, but not spine size
(Choi et al., 2005). Similar to these results, excitatory synapses
develop slowly in dissociated hippocampal neurons derived fromIRSp53/ mice (Sawallisch et al., 2009). IRSp53/ mice display
normal densities of excitatory synapses and dendritic spines in the
hippocampus (Kim et al., 2009a; Sawallisch et al., 2009) but
reduced excitatory synapse and spine densities in the medial pre-
frontal cortex (Chung et al., 2015). This indicates distinct inﬂuences
of IRSp53 deletion on different brain regions. Phenotypes of
IRSp53/ mice are summarized in Table 2.
How might IRSp53 contribute to synaptogenesis? The CRIB-PR
domain of IRSp53 can bind to activated Cdc42, which is tethered to
the plasma membrane at sites of early synapses, promoting the
membrane targeting and activation of IRSp53. This would allow the
IMD domain of IRSp53 bind to and deform PI(4,5)P2- and PI(3,4,5)P3-
rich plasma membranes to generate protrusive structures (Fig. 2).
Concurrent with this, the IMD domain may interact with and bundle
(or form a linear array of) actin ﬁlaments at sites of membrane
deformation. This physical connection of the plasma membrane and
actin ﬁlaments, which may also occur in mature synapses, would
require a large amount of IRSp53 protein. Consistent with this pos-
sibility, IRSp53 is quite abundant in the PSD, where its levels are
comparable to those of other scaffolding/adaptor proteins such as
PSD-95, GKAP, Shank, and Homer (Cheng et al., 2006).
The SH3 domain of activated IRSp53 may also promote actin
polymerization at sites of IRSp53 clustering in early and mature
synapses in a neuronal activity- and Rac/Cdc42-dependent manner
(Fig. 2). SH3 effectors such as Eps8, Ena/VASP, and mDia1, acting
downstream of Cdc42, may drive the formation of linear actin ﬁl-
aments (Ahmed et al., 2010; Scita et al., 2008), while N-WASP and
WAVE2, acting downstream of Rac, may promote branched actin
ﬁlaments. In direct support of an important role of the SH3 domain
in spine regulation, a mutant IRSp53 with a point mutation in the
SH3 domain that abolishes effector binding, or a fragment of
WAVE2 containing only the IRSp53-SH3-interacting proline-rich
region, suppresses dendritic spine density in a dominant-negative
manner when overexpressed in cultured hippocampal neurons
(Choi et al., 2005).
In line with the critical roles of Cdc42 and Rac in IRSp53-
dependent spine development mentioned above, activation of
NMDARs and EphB receptors are known to stimulate Rac/Cdc42
through mechanisms including calcium/calmodulin-dependent
kinases I/II (CaMKI/II) and a variety of GEFs such as Kalirin-7,
Tiam1, GEFT, and a/bPix (ARHGEF6/7) (Penzes and Cahill, 2012;
Table 2
Electrophysiological and behavioral phenotypes of IRSp53/ mice.
Phenotypes of IRSp53/ mice Changes References
Electrophysiological phenotypes AMPA-mEPSC in CA1 Normal (Kim et al., 2009a)
NMDA-mEPSC in CA1 Increased (ampl.) (Kim et al., 2009a)
PPF in DG in vivo Increased (Sawallisch et al., 2009)
PPF in CA1 Increased (Sawallisch et al., 2009)
NMDA/AMPA ratio in CA1 Increased (Kim et al., 2009a)
LTP in DG in vivo Increased (Sawallisch et al., 2009)
LTP in CA1 Increased (Kim et al., 2009a; Sawallisch et al., 2009)
LTD in CA1 Normal (Kim et al., 2009a)
mGluR-LTD in CA1 Normal (Chung et al., 2015)
LTD of NMDAR EPSCs in CA1 Impaired (Chung et al., 2015)
AMPA-mEPSC in mPFC Decreased freq. & ampl. (Chung et al., 2015)
Firing rate in mPFC in vivo Decreased (Chung et al., 2015)
Behavioral phenotypes Open ﬁeld locomotion Normal; Hyperactive (Sawallisch et al., 2009); (Chung et al., 2015)
Rotarod motor function Normal (Sawallisch et al., 2009)
Contextual fear Increased (Sawallisch et al., 2009)
Morris water maze memory Impaired (Kim et al., 2009a)
Novel object recognition Impaired (Kim et al., 2009a)
3-chamber social interaction Decreased (Chung et al., 2015)
USV calls (to female) Decreased (Chung et al., 2015)
Fig. 2. A model for the proposed roles of IRSp53 in the development of dendritic spines. IRSp53 likely binds to and deforms the dendritic plasma membrane through the N-terminal
IMD domain, producing a protrusive structure (membrane deformation). Once the activated (GTP-bound) form of Cdc42, which acts in the downstream of membrane proteins such as
NMDARs, binds to and opens up IRSp53, IRSp53 will interact with and recruit diverse actin modulatory SH3 effectors. Effectors including Ena/VASP, mDia2, and Eps8 may promote
linear actin ﬁlament formation (linear actin ﬁlament formation), likely driving the elongation and bundling of early dendritic protrusions. Others such as WAVE and N-WASP, acting in
the downstream of Rac, may drive the formation of branched actin ﬁlaments in relatively mature dendritic spines by acting on the Arp2/3 complex (branched actin ﬁlament for-
mation). IRSp53 is also thought to bridge the plasma membrane and actin ﬁlaments in dendritic spines through its IMD domain (actin-membrane bridge). The dual interaction of
IRSp53 with the excitatory postsynaptic scaffolds PSD-95 and Shank may allow the formation of tighter and bigger structural and signaling complexes.
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2012; Tolias et al., 2011). Conversely, Rac/Cdc42 activities can be
suppressed by diverse GTPase activating proteins (GAPs), including
intersectin, a1-chimaerin, Bcr/Abr, SRGAP2/3, and RhoGAP2,
balancing the actions of Rac GEFs.
The C-terminal PDZ-binding motif of IRSp53 binds to the PDZ
domains of the excitatory postsynaptic scaffolds PSD-95 and PSD-
93/Chapsyn-110 (Choi et al., 2005; Soltau et al., 2004), in-
teractions that appear to promote synaptic localization of IRSp53
(Choi et al., 2005; Hori et al., 2005) (Fig. 2). Conversely, IRSp53 may
also recruit and stabilize PSD-95 at sites of early synaptic pro-
trusions or mature dendritic spines where membrane deformation
and actin polymerization/stabilization is occurring. IRSp53 may
also form a ternary complex with PSD-95 and Shank (Soltau et al.,
2004), leading to the formation of a bigger scaffolding/signaling
complex in the PSD.
Given that the SH3 domain of IRSp53 can interact with diverse
actin-regulatory proteins, it will be important to understand how
various SH3 effectors cooperate with Rac/Cdc42 and IRSp53 to
regulate the dynamics of branched and linear actin ﬁlaments dur-
ing different stages of spine development and at multiple sub-spine
domains. In addition, the types of SH3 effectors bound to IRSp53
and their phosphorylation states determine the direction and rate
of actin ﬁlament growth during ﬁlopodia formation (Ahmed et al.,
2010). It is therefore conceivable that synaptic receptors and
associated signaling pathways acting upstream of IRSp53 may
further coordinate IRSp53-dependent spine regulation.
7. IRSp53 in the regulation of excitatory synaptic
transmission and plasticity
Given the importance of the actin cytoskeleton and its dynamics
in the regulation of excitatory synaptic transmission and plasticity
(Calabrese et al., 2006; Cingolani and Goda, 2008; Hotulainen and
Hoogenraad, 2010; Oertner and Matus, 2005; Penzes and
Rafalovich, 2012; Sala and Segal, 2014; Saneyoshi and Hayashi,
2012; Tada and Sheng, 2006), IRSp53 deletion in neurons could
be expected to modify synaptic functions.
Indeed, overexpression of IRSp53, or a mutant form of IRSp53
that lacks the SH3 domain and is constitutively targeted to excit-
atory synapses, in cultured hippocampal neurons increases the
amplitude of miniature excitatory postsynaptic currents (mEPSCs)
(Hori et al., 2005), suggesting that IRSp53 positively regulates
excitatory synaptic transmission. In contrast to these in vitro re-
sults, IRSp53/ Schaffer collateral-CA1 pyramidal synapses in the
hippocampus show normal amplitude and frequency of mEPSCs,
inputeoutput relationship of basal transmission, and paired pulse
facilitation (PPF) (Kim et al., 2009a) (summarized in Table 2).
Similar results were reported by another laboratory (Sawallisch
et al., 2009), although this latter study did ﬁnd an increase in PPF.
IRSp53/ synapses on dentate gyrus granule cells receiving inputs
from the medial perforant pathway show unaltered basal trans-
mission but increased PPF (Sawallisch et al., 2009). Collectively,
these results suggest that AMPA (a-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid) receptor (AMPAR)-mediated synaptic
transmission is largely normal in the hippocampus.
Intriguingly, however, NMDAR-mediated excitatory synaptic
transmission is enhanced at IRSp53/ SC-CA1 synapses, as
measured by pharmacologically isolated NMDAR-dependent
mEPSCs and evoked EPSCs (Kim et al., 2009a). In addition, long-
term potentiation (LTP) is markedly enhanced, although long-
term depression (LTD) is unaffected. These results suggest that
NMDAR function is selectively enhanced at IRSp53/ hippocampal
synapses (Kim et al., 2009a; Sawallisch et al., 2009).
The IRSp53/mPFC region shows changes distinct from those inthe hippocampus (Chung et al., 2015) (Table 2). The frequency and
amplitude of mEPSCs are markedly reduced in IRSp53/ prelimbic
layer2/3 neurons, an effect that is paralleled by a decrease in
excitatory synapse numbers, as shown by EM analysis. Unlike the
case in the hippocampus, NMDAR function in themPFC is unaltered,
as measured by the NMDA/AMPA ratio. Therefore, the two IRSp53/
 brain regions display distinct electrophysiological changes: the
hippocampus shows a decrease in NMDAR functionwith no change
in excitatory synapse numbers, whereas the mPFC displays normal
NMDAR function but a decrease in excitatory synapse numbers.8. Mechanisms underlying NMDAR hyperactivity in IRSp53¡/¡
hippocampal neurons
How might IRSp53 deletion lead to NMDAR hyperactivity in
mice? The molecular abundance and functional properties of
NMDARs at excitatory synapses are determined by a large number
of factors, including subunit composition, protein modiﬁcation,
interacting proteins, and receptor trafﬁcking into and out of syn-
apses (Bard and Groc, 2011; Chen and Roche, 2007; Fan et al., 2014;
Horak et al., 2014; Husi and Grant, 2001; Husi et al., 2000; Lau and
Zukin, 2007; Newpher and Ehlers, 2008; Paoletti et al., 2013; Ryan
et al., 2008; Sanz-Clemente et al., 2013). Therefore, comprehen-
sively identifying all underlying mechanisms would be a daunting
task, but it is possible that theremay be increased inﬂux, or reduced
efﬂux, of NMDARs at IRSp53/ synapses under basal conditions or
during neuronal activity.
Previous studies have shown that actin ﬁlaments are important
for synaptic localization and activity of NMDARs as well as AMPARs
(Allison et al., 1998; Bosch and Hayashi, 2012; Furukawa et al., 1997;
Rosenmund and Westbrook, 1993; Wyszynski et al., 1997).
Consistent with this idea, actin ﬁlaments in IRSp53/ hippocampal
neurons are abnormally stable, exhibiting resistance to NMDA-
induced dispersal (Chung et al., 2015). Given that the NMDA
treatment induces a normal increase in coﬁlin activation/dephos-
phorylation in IRSp53/ hippocampal neurons (Chung et al., 2015),
it appears that actin ﬁlaments in these neurons became resistant to
activated coﬁlin. In addition, IRSp53/ SC-CA1 synapses show
reduced LTD of NMDAR EPSCs (Chung et al., 2015), a form of syn-
aptic LTD distinct from the better-understood LTD of AMPAR EPSCs
in aspects including the underlying mechanisms; LTD of NMDAR
EPSCs requires actin depolymerization, whereas LTD of AMPAR
EPSCs requires calcineurin activation (Morishita et al., 2005; Selig
et al., 1995). These results suggest the hypothesis that IRSp53
deletion leads to an abnormal stabilization of synaptic actin ﬁla-
ments, which may promote synaptic localization of NMDARs and
suppress their activity-dependent removal (Fig. 3).
Given that IRSp53 interacts with a large number of proteins and
that IRSp53 may regulate their stability, synaptic localization, and
function, IRSp53-interacting proteins may contribute to the
enhanced NMDAR function observed at IRSp53/ hippocampal
synapses. In line with this possibility, mice lacking Eps8, which
directly interacts with IRSp53 (Funato et al., 2004), show abnor-
mally stable actin ﬁlaments, reduced NMDA-induced coﬁlin acti-
vation/dephosphorylation, enhanced NMDAR function in cerebellar
granule neurons, and increased ethanol resistance and consump-
tion (Offenhauser et al., 2006). In addition, mice lacking WAVE-1,
which interacts with IRSp53 (Miki et al., 2000) and regulates
dendritic spines (Hazai et al., 2013; Kim et al., 2006; Soderling et al.,
2007), display elevated NMDAR function and enhanced early and
late LTP (Soderling et al., 2007). Dynamin-1, known to interact with
IRSp53 (Chou et al., 2014), is required for NMDAR internalization
induced by the dual binding of glutamate and glycine (Nong et al.,
2003).
Fig. 3. A model for the proposed roles of abnormally stabilized actin ﬁlaments in anchoring of NMDARs at excitatory synapses. Under normal conditions, NMDARs are anchored at
excitatory synapses through their interactions with PSD-95 family proteins and actin ﬁlaments through a-actinins. Stimuli inducing the LTD of NMDAR EPSCs cause actin depo-
lymerization through the activation/dephosphorylation of coﬁlin (a negative actin regulator), leading to the removal of NMDARs from synapses through lateral diffusion. In the
absence of IRSp53, synaptic actin ﬁlaments are abnormally stabilized through as of yet unclear mechanisms and become resistant to activated/dephosphorylated coﬁlin (dotted
arrow), leading to enhanced synaptic retention of NMDARs under basal conditions and suppressed removal of NMDARs from synapses during LTD of NMDAR EPSCs.
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Recent clinical studies have associated IRSp53/BAIAP2 with
normal human brain functions (Luksys et al., 2014) and several
psychiatric disorders, including ASDs (Celestino-Soper et al., 2011;
Levy et al., 2011; Toma et al., 2011), schizophrenia (Fromer et al.,
2014; Purcell et al., 2014), and ADHD (Liu et al., 2013; Ribases
et al., 2009). A common SNP (single-nucleotide polymorphism)
variant located in the BAIAP2 gene in healthy individuals has been
associated with emotional regulation of human memory strength
(Luksys et al., 2014). In this study, modulation of verbal memory
strength by negative information was associated with SNP geno-
type, activity of the parahippocampal cortex, and BAIAP2 mRNAs
levels.
In individuals with ASDs and schizophrenia, several SNPs were
associated with disease susceptibilities (Ribases et al., 2009; Toma
et al., 2011). In addition, de novo copy number variations (de-
letions) that eliminate the entire IRSp53 gene were identiﬁed in in-
dividuals with ASD (Celestino-Soper et al., 2011; Levy et al., 2011). De
novo missense and nonsense mutations in the IRSp53 gene that lead
to an F486L aa substitution in a region following the WW domain
and truncation of the protein in the IMD domain, respectively, have
also been identiﬁed in schizophrenic patients (Fromer et al., 2014;
Purcell et al., 2014). Additional details are summarized in Table 3.
10. Behavioral phenotypes of IRSp53¡/¡ mice
Behavioral phenotypes of IRSp53/ mice have been character-
ized (Chung et al., 2015; Kim et al., 2009a; Sawallisch et al., 2009).
IRSp53/ mice show impaired social interaction, as determined by
three-chamber and direct social interaction tests (Chung et al.,
2015) (Table 2). In addition, ultrasonic vocalization in the pres-
ence of a stranger female is reduced in male IRSp53/ mice.However, IRSp53/ mice do not show enhanced repetitive be-
haviors, such as grooming and digging.
IRSp53/ mice have been reported to display hyperactivity in
both novel and familiar environments (Chung et al., 2015), though
another study reported largely normal locomotor activity of
IRSp53/ mice in a novel environment (Sawallisch et al., 2009).
Given that the two studies usemice produced from the same ES cell
line (XG757; BayGenomics), the discrepancy might stem from their
different genetic backgrounds: C57BL/6J (Chung et al., 2015) and
129P2/C57BL/6 hybrid (Sawallisch et al., 2009).
In terms of cognitive function, IRSp53/ mice show impair-
ments inMorris watermaze spatial learning (Kim et al., 2009a), and
novel object recognition memory (Kim et al., 2009a). Intriguingly,
IRSp53/ mice show increased contextual fear conditioning 24 h
after the training (Sawallisch et al., 2009).
These results collectively suggest that IRSp53/ mice exhibit
social and cognitive deﬁcits and hyperactivity, which may have
features in common with the symptoms of IRSp53-associated
psychiatric disorders (e.g., ASDs, schizophrenia, and ADHD).
Although these behavioral phenotypes tend to support the validity
of the IRSp53/ mouse model, the predictive value of this model
depends on a demonstration of pharmacological reversal of the
phenotypes.
11. Reversal of abnormal phenotypes in IRSp53¡/¡ mice by
NMDAR suppression
Starting from the premise that abnormal behaviors of IRSp53/
mice are caused by elevated NMDAR function, a logical intervention
is to attempt to normalize these behaviors by pharmacological
suppression of NMDAR function. Memantine, an uncompetitive
antagonist of NMDARs, is used clinically to improve cognitive
functions in brain disorders, including Alzheimer's disease, and is
Table 3
Associations of IRSp53 with psychiatric disorders.
Disorders Genetic variations Locations of mutations References
ASD SNP (rs11657991) Intron 2 (Toma et al., 2011)
De novo CNV (deletion) Not applicable (Celestino-Soper et al., 2011)
De novo CNV (deletion) Not applicable (Levy et al., 2011)
Schizophrenia Missense (F486L) Exon 12 (After WW domain) (Fromer et al., 2014)
Codon deletion (CCCT/ C) 30-UTR (chr17:79089626e79089629)
Nonsense (G/ T) Exon 2 (IMD domain; chr17:79027528) (Purcell et al., 2014)
ADHD SNP (rs8079626, rs11657991, rs7503597, rs7210438) Introns 1, 2, 3, 5 (Ribases et al., 2009)
SNP (rs4969239, rs3934492, rs4969385) Introns 1, 3, 6 (Liu et al., 2013)
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voltage-dependent channel-blocking property (Parsons et al., 2013;
Thomas and Grossberg, 2009).
Consistent with the NMDAR hyperfunction hypothesis, acute
memantine treatment (10 mg/kg) 30 min before behavioral testing
signiﬁcantly improves the social interaction of IRSp53/ mice in
the three-chamber test, without affecting that of wild-type mice
(Chung et al., 2015). In addition, memantine normalizes the
impaired novel object recognition in IRSp53/ mice, suggesting an
effect on cognitive functions. However, memantine has no effect on
the hyperactivity in these animals.
Indirect suppression of NMDAR function in IRSp53/ mice by
MPEP (2-methyl-6-(phenylethynyl)pyridine), a negative allosteric
modulator of metabotropic glutamate receptor 5 (mGluR5), a re-
ceptor type that acts synergistically with NMDARs (Alagarsamy
et al., 1999; Jia et al., 1998; Kotecha and MacDonald, 2003; Lu
et al., 1999; O'Connor et al., 1994), rescues social interaction deﬁ-
cits in IRSp53/ mice. This provides further evidence for an asso-
ciation between NMDAR hyperfunction and the social deﬁcits in
IRSp53/ mice.
How could the IRSp53/ mPFC, which shows normal NMDAR
function, be involved in the memantine-dependent rescue of social
deﬁcits in these animals? IRSp53/ neurons in the mPFC display
reduced excitatory neuronal ﬁring with unaltered inhibitory
neuronal ﬁring (Chung et al., 2015). In addition, this phenotype is
rescued by acute memantine treatment. This links normalization of
neuronal ﬁring in the IRSp53/ mPFC with the memantine-
dependent NMDAR suppression and rescue of social and cogni-
tive deﬁcits in IRSp53/mice, although further mechanistic details
remain to be elucidated.
12. Therapeutic potential of NMDAR suppression for social
and cognitive deﬁcits associated with ASDs, schizophrenia,
and ADHD
Results from IRSp53 studies suggest the therapeutic potential of
NMDAR suppression in alleviating social and cognitive deﬁcits
associated with ASDs, schizophrenia, and ADHD. The therapeutic
potential of memantine in the treatment of psychiatric disorders
has gained credence, but remains controversial (Canitano, 2014;
Doyle and McDougle, 2012; Hosenbocus and Chahal, 2013;
Rossignol and Frye, 2014; Sani et al., 2012; Shim and Nadeem,
2014). As such, the following issues, which are in principle test-
able in model animals, need to be clariﬁed.
First of all, it is unclear where in the brain the abnormally
enhanced NMDAR function resides and how it is associated with
the observed social and cognitive impairments. In the case of
IRSp53, the protein is detected in different regions of the brain
(cortex, hippocampus, striatum, and cerebellum), cell types (spiny
excitatory and inhibitory neurons), and lateral locations within the
PSD (higher in the center vs. evenly distributed) (Burette et al.,
2014), suggesting that IRSp53 may have distinct functions at
different spatial locations.Second, the list of animals that show enhanced NMDAR function
and social and cognitive deﬁcits that are improved by NMDAR-
suppressing medications needs to be expanded. For instance, rats
prenatally exposed to valproic acid (an antiepileptic agent with
teratogenic activity), which show ASD-like phenotypes (social and
repetitive behavior deﬁcits), display enhanced NMDAR levels and
LTP in the cortex (Rinaldi et al., 2007), indicative of enhanced
NMDAR function. In addition, social defects and repetitive behav-
iors in mice prenatally exposed to valproic acid are suppressed by
NMDAR inhibition through acute treatment with memantine or
MPEP treatment (Kang and Kim, 2015; Kim et al., 2014).
This new possibilitydNMDAR suppression to alleviate social
and cognitive deﬁcits in psychiatric disordersdneeds to be recon-
ciled with other emerging and established factors contributing to
ASDs, schizophrenia, and ADHD such as excitation-inhibition bal-
ance (Bourgeron, 2009; Gao and Penzes, 2015; Rubenstein, 2010;
Rubenstein and Merzenich, 2003; Yizhar et al., 2011), hyper-
dopamine/hypo-glutamate (Coyle, 2012; Coyle et al., 2012), and
hypo-dopamine mechanisms (Chang et al., 2014; Levy, 2014),
respectively.
Memantine acts on other types of receptors in addition to
NMDARs, functioning as antagonists at serotonin (5-HT3) and
nicotinic acetylcholine receptors, and as an agonist at dopamine
(D2) receptors (McKeage, 2009, 2010). The potential involvement of
these activities in the observed rescue effects in IRSp53/ mice
should be clariﬁed, although the similar rescue produced by the
suppression of mGluR5, which acts synergistically with NMDARs,
supports the NMDAR hyperfunction hypothesis (Chung et al., 2015).
In addition to enhanced NMDAR function, reduced NMDAR
function has also been associated with ASD-like phenotypes in
animal models of ASDs (Blundell et al., 2010; Lee et al., 2015; Won
et al., 2012). Therefore, how deviation of NMDAR function in either
directiondenhancement or suppressiondis associated with
similar social deﬁcits should be clariﬁed.
Lastly, clinical trials of memantine for ASD treatment have
yielded signiﬁcant improvements in 8 out of 9 studies (Rossignol
and Frye, 2014); higher-quality and larger-scale clinical studies
should follow. Despite these encouraging results, memantine has
been found to both improve and worsen irritability, suggesting that
memantine may work for a speciﬁc subgroup of patients. The
possible bidirectional deviation of NMDAR function in the social
deﬁcits noted above might explain the clinical data.13. Conclusion
This review summarized the suggested roles of IRSp53 in the
regulation of synaptic actin/membranes, spine development, and
synaptic function and plasticity. In addition, we described the role
of NMDAR suppression in the reversal of the social and cognitive
deﬁcits observed in IRSp53/mice, which may help us understand
IRSp53-related and other actin/NMDAR-related psychiatric
disorders.
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